Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

LRRTM4: A Novel Regulator of Presynaptic Inhibition and Ribbon Synapse Arrangements of Retinal Bipolar Cells.

Sinha R, Siddiqui TJ, Padmanabhan N, Wallin J, Zhang C, Karimi B, Rieke F, Craig AM, Wong RO, Hoon M.

Neuron. 2020 Jan 8. pii: S0896-6273(19)31094-3. doi: 10.1016/j.neuron.2019.12.028. [Epub ahead of print]

PMID:
31974009
2.

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.

Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H, Kimmich M, Girard N, Tsai CM, Hsia TC, Brighenti M, Schumann C, Wang XA, Wijayawardana SR, Gruver AM, Wallin J, Mansouri K, Wacheck V, Chang GC.

J Thorac Oncol. 2020 Jan;15(1):80-90. doi: 10.1016/j.jtho.2019.10.003. Epub 2019 Oct 14.

PMID:
31622732
3.

Source Apportionment of Polychlorinated Biphenyls in Atmospheric Deposition in the Seattle, WA, USA Area Measured with Method 1668.

Rodenburg LA, Winstanley I, Wallin JM.

Arch Environ Contam Toxicol. 2019 Aug;77(2):188-196. doi: 10.1007/s00244-019-00640-x. Epub 2019 Jun 5.

PMID:
31165912
4.

A Clinical Comparison and Economic Evaluation of Erich Arch Bars, 4-Point Fixation, and Bone-Supported Arch Bars for Maxillomandibular Fixation.

Edmunds MC, McKnight TA, Runyan CM, Downs BW, Wallin JL.

JAMA Otolaryngol Head Neck Surg. 2019 Jun 1;145(6):536-541. doi: 10.1001/jamaoto.2019.0183.

PMID:
30946454
5.

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER.

Oncologist. 2019 Sep;24(9):e930-e942. doi: 10.1634/theoncologist.2018-0411. Epub 2019 Mar 4.

6.

A comparative study for the isolation of exogenous trace DNA from fingernails.

Hayden DD, Wallin JM.

Forensic Sci Int Genet. 2019 Mar;39:119-128. doi: 10.1016/j.fsigen.2018.12.009. Epub 2019 Jan 4.

PMID:
30640083
7.

A Bayesian method to localize lost gamma sources.

Bukartas A, Finck R, Wallin J, Rääf CL.

Appl Radiat Isot. 2019 Mar;145:142-147. doi: 10.1016/j.apradiso.2018.11.008. Epub 2018 Nov 29.

8.

Lumbriculus variegatus (Annelida) biological responses and sediment sequential extractions indicate ecotoxicity of lake sediments contaminated by biomining.

Wallin J, Vuori KM, Väisänen A, Salmelin J, Karjalainen AK.

Sci Total Environ. 2018 Dec 15;645:1253-1263. doi: 10.1016/j.scitotenv.2018.07.117. Epub 2018 Jul 21.

PMID:
30248850
9.

Predation by avian insectivores on caterpillars is linked to leaf damage on oak (Quercus robur).

Gunnarsson B, Wallin J, Klingberg J.

Oecologia. 2018 Nov;188(3):733-741. doi: 10.1007/s00442-018-4234-z. Epub 2018 Aug 16.

10.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J.

Eur J Cancer. 2018 Sep;101:114-122. doi: 10.1016/j.ejca.2018.06.033. Epub 2018 Jul 24.

PMID:
30053670
11.

Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.

Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE.

J Pharmacol Exp Ther. 2018 Jul;366(1):96-104. doi: 10.1124/jpet.118.248286. Epub 2018 Apr 24.

PMID:
29691287
12.

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.

Hegde PS, Wallin JJ, Mancao C.

Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124. doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8. Review.

PMID:
29229461
13.

Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.

Chigutsa E, Long AJ, Wallin JE.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):560-568. doi: 10.1002/psp4.12209. Epub 2017 Jul 13.

14.

Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex platform.

Gupta V, Davancaze T, Good J, Kalia N, Anderson M, Wallin JJ, Brady A, Song A, Xu W.

Bioanalysis. 2016 Dec;8(23):2415-2428.

PMID:
27855508
15.

Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.

Cowan K, Gao X, Parab V, Nguy T, Wu L, Arron JR, Townsend M, Wallin J, Cheu M, Morimoto A, Wakshull E.

Bioanalysis. 2016 Nov;8(22):2329-2340. doi: 10.4155/bio-2016-0184. Epub 2016 Oct 7.

PMID:
27712082
16.

Population Pharmacokinetics of Necitumumab in Cancer Patients.

Long A, Chigutsa E, Wallin J.

Clin Pharmacokinet. 2017 May;56(5):505-514. doi: 10.1007/s40262-016-0452-x.

17.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF.

Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.

18.

Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, Salphati L, Wallin JJ, Phillips HS, Wick W, Winkler F.

Clin Cancer Res. 2016 Dec 15;22(24):6078-6087. Epub 2016 Aug 12.

19.

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.

Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ.

Genes Cancer. 2016 Mar;7(3-4):73-85. doi: 10.18632/genesandcancer.100.

20.

Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.

Smith DC, Powderly J, Lee JJ, Shepard DR, Wallin J, Chaudhary A, Chao GY, Ng WT, Mitchell MI, Grau G, Kurek R, LoRusso P.

Cancer Chemother Pharmacol. 2016 Aug;78(2):271-80. doi: 10.1007/s00280-016-3074-y. Epub 2016 Jun 16.

PMID:
27312733
21.

Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.

Gnad F, Wallin J, Edgar K, Doll S, Arnott D, Robillard L, Kirkpatrick DS, Stokes MP, Vijapurkar U, Hatzivassiliou G, Friedman LS, Belvin M.

Proteomics. 2016 Jul;16(14):1992-7. doi: 10.1002/pmic.201600118. Epub 2016 Jul 8.

PMID:
27282143
22.

Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms.

Gnad F, Doll S, Song K, Stokes MP, Moffat J, Liu B, Arnott D, Wallin J, Friedman LS, Hatzivassiliou G, Belvin M.

Proteomics. 2016 Jul;16(14):1998-2004. doi: 10.1002/pmic.201600119.

PMID:
27273156
23.

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD, Lewis C, Nonomiya J, Pang J, Plise EG, Sideris S, Wallin J, Wang L, Zhang X, Olivero AG.

ACS Med Chem Lett. 2016 Feb 16;7(4):351-6. doi: 10.1021/acsmedchemlett.6b00005. eCollection 2016 Apr 14.

24.

Erratum to: BayesFlow: latent modeling of flow cytometry cell populations.

Johnsson K, Wallin J, Fontes M.

BMC Bioinformatics. 2016 Mar 31;17:149. doi: 10.1186/s12859-016-0973-1. No abstract available.

25.

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.

Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J.

Br J Cancer. 2016 Feb 16;114(4):372-80. doi: 10.1038/bjc.2015.480. Epub 2016 Jan 14.

26.

BayesFlow: latent modeling of flow cytometry cell populations.

Johnsson K, Wallin J, Fontes M.

BMC Bioinformatics. 2016 Jan 12;17:25. doi: 10.1186/s12859-015-0862-z. Erratum in: BMC Bioinformatics. 2016;17:149.

27.

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).

Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, Edgar K, Eigenbrot C, Friedman L, Gancia E, Jackson PS, Jones G, Kolesnikov A, Lee LB, Lesnick JD, Lewis C, McLean N, Mörtl M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Staben ST, Steinbacher S, Tsui V, Wallin J, Sampath D, Olivero AG.

J Med Chem. 2016 Feb 11;59(3):985-1002. doi: 10.1021/acs.jmedchem.5b01483. Epub 2016 Jan 20.

PMID:
26741947
28.

The bibliometric analysis of scholarly production: How great is the impact?

Ellegaard O, Wallin JA.

Scientometrics. 2015;105(3):1809-1831. Epub 2015 Jul 28.

29.

PD-L1 inhibition with MPDL3280A for solid tumors.

Cha E, Wallin J, Kowanetz M.

Semin Oncol. 2015 Jun;42(3):484-7. doi: 10.1053/j.seminoncol.2015.02.002. Epub 2015 Feb 12. Review.

PMID:
25965367
30.

Malpractice in treatment of sinonasal disease by otolaryngologists: a review of the past 10 years.

Winford TW, Wallin JL, Clinger JD, Graham AM.

Otolaryngol Head Neck Surg. 2015 Mar;152(3):536-40. doi: 10.1177/0194599814566787. Epub 2015 Jan 8.

PMID:
25573677
31.

Weight-of-evidence approach in assessment of ecotoxicological risks of acid sulphate soils in the Baltic Sea river estuaries.

Wallin J, Karjalainen AK, Schultz E, Järvistö J, Leppänen M, Vuori KM.

Sci Total Environ. 2015 Mar 1;508:452-61. doi: 10.1016/j.scitotenv.2014.11.073. Epub 2014 Dec 12.

PMID:
25506908
32.

Classification of large acoustic datasets using machine learning and crowdsourcing: application to whale calls.

Shamir L, Yerby C, Simpson R, von Benda-Beckmann AM, Tyack P, Samarra F, Miller P, Wallin J.

J Acoust Soc Am. 2014 Feb;135(2):953-62. doi: 10.1121/1.4861348.

PMID:
25234903
33.

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.

Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, Sampath D, Friedman LS, Wallin JJ.

Genes Cancer. 2014 Mar;5(3-4):113-26.

34.

Stability of aspiration status in healthy adults.

Todd JT, Stuart A, Lintzenich CR, Wallin J, Grace-Martin K, Butler SG.

Ann Otol Rhinol Laryngol. 2013 May;122(5):289-93.

PMID:
23815044
35.

Identification of environmentally relevant chemicals in bibliographic databases: a comparative analysis.

Ellegaard O, Wallin JA.

Springerplus. 2013 Jun 5;2(1):255. doi: 10.1186/2193-1801-2-255. Print 2013 Dec.

36.

Patient outcomes, satisfaction, and improvement in headaches after endoscopic brow-lift.

Panella NJ, Wallin JL, Goldman ND.

JAMA Facial Plast Surg. 2013 Jul-Aug;15(4):263-7. doi: 10.1001/jamafacial.2013.924.

PMID:
23699709
37.

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.

Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG.

J Med Chem. 2013 Jun 13;56(11):4597-610. doi: 10.1021/jm4003632. Epub 2013 Jun 3.

PMID:
23662903
38.

Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.

Staben ST, Ndubaku C, Blaquiere N, Belvin M, Bull RJ, Dudley D, Edgar K, Gray D, Heald R, Heffron TP, Jones GE, Jones M, Kolesnikov A, Lee L, Lesnick J, Lewis C, Murray J, McLean NJ, Nonomiya J, Olivero AG, Ord R, Pang J, Price S, Prior WW, Rouge L, Salphati L, Sampath D, Wallin J, Wang L, Wei B, Weismann C, Wu P.

Bioorg Med Chem Lett. 2013 May 1;23(9):2606-13. doi: 10.1016/j.bmcl.2013.02.102. Epub 2013 Mar 7.

PMID:
23540645
39.

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.

Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, Skelton NJ, Wallin JJ, Belvin M, Punnoose E, Friedman LS, Lin K.

Clin Cancer Res. 2013 Apr 1;19(7):1760-72. doi: 10.1158/1078-0432.CCR-12-3072. Epub 2013 Jan 3.

40.

Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.

Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS.

Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19.

41.

The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.

Heffron TP, Salphati L, Alicke B, Cheong J, Dotson J, Edgar K, Goldsmith R, Gould SE, Lee LB, Lesnick JD, Lewis C, Ndubaku C, Nonomiya J, Olivero AG, Pang J, Plise EG, Sideris S, Trapp S, Wallin J, Wang L, Zhang X.

J Med Chem. 2012 Sep 27;55(18):8007-20. Epub 2012 Sep 11.

PMID:
22946614
42.

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.

Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, Koeppen H, Belvin M, Friedman LS, Sampath D.

Clin Cancer Res. 2012 Jul 15;18(14):3901-11. doi: 10.1158/1078-0432.CCR-11-2088. Epub 2012 May 14.

43.

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, Belvin M, Friedman LS.

PLoS One. 2012;7(5):e36402. doi: 10.1371/journal.pone.0036402. Epub 2012 May 3.

44.

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.

Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M, Haverty PM, Fedorowicz G, Heldens S, Soriano RH, Zhang Z, Wallin JJ, Johnson L, Merchant M, Modrusan Z, Stern HM, Seshagiri S.

Oncogene. 2013 Jan 17;32(3):318-26. doi: 10.1038/onc.2012.53. Epub 2012 Feb 27.

45.

Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.

Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE.

Ther Drug Monit. 2011 Dec;33(6):663-72. doi: 10.1097/FTD.0b013e31823415cc.

PMID:
22105583
46.

The Matthew effect in environmental science publication: a bibliometric analysis of chemical substances in journal articles.

Grandjean P, Eriksen ML, Ellegaard O, Wallin JA.

Environ Health. 2011 Nov 10;10:96. doi: 10.1186/1476-069X-10-96.

47.

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.

Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.

48.

Swedish midwives' rating of risks during labour progress and their attitudes toward performing intrapartum interventions: a web-based survey.

Wiklund I, Wallin J, Vikström M, Ransjö-Arvidson AB.

Midwifery. 2012 Aug;28(4):E456-60. doi: 10.1016/j.midw.2011.06.008. Epub 2011 Aug 5.

PMID:
21820774
49.

[Home blood pressure monitoring as good as office monitoring].

Wallin J, Drevenhorn E, Nyström F.

Lakartidningen. 2011 Mar 2-8;108(9):469-70. Swedish. No abstract available.

PMID:
21744612
50.

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO.

AAPS J. 2011 Jun;13(2):143-51. doi: 10.1208/s12248-011-9255-z. Epub 2011 Feb 8.

Supplemental Content

Loading ...
Support Center